Company Overview
Stryker Corporation functions as a prominent medical technology enterprise with a global footprint spanning the United States and international markets. The organization is structured into distinct operational segments, specifically MedSurg and Neurotechnology, as well as Orthopaedics, which collectively deliver surgical equipment, patient safety technologies, and navigational solutions. This entity operates within the broader Healthcare sector and the specialized Medical Devices industry, positioning it to serve critical needs in clinical environments worldwide. The company demonstrates substantial scale with a market capitalization of $125.40B and trailing twelve-month revenue of $25.12B, supported by a workforce of 56,000 employees. These valuation and revenue figures indicate that Stryker holds a significant market position, commanding a large aggregate market value that reflects its established presence and capacity to generate billions in annual sales.
Financial Health
Stryker Corporation reported trailing twelve-month revenue of $25.12B, net income of $3.25B, and EBITDA of $6.95B, highlighting a robust top-line performance relative to bottom-line profitability. The substantial gap between the $25.12B revenue figure and the $3.25B net income reveals a cost structure where operating expenses, taxes, and interest charges collectively consume approximately 87.1% of gross revenue, leaving the remaining portion as net profit. The company generated free cash flow of $4.17B, a metric that signifies strong operational cash generation capable of funding capital expenditures, research initiatives, or debt reduction without relying solely on external financing. Regarding liquidity, Stryker holds $4.10B in cash against $16.36B in debt, resulting in a debt-to-equity ratio of 72.97, which suggests a balance sheet that utilizes leverage to finance operations while maintaining a manageable debt load relative to equity. The current ratio stands at 1.89, indicating that the company possesses $1.89 in current assets for every $1.00 of current liabilities, which points to a conservative stance on short-term liquidity and the ability to meet upcoming obligations comfortably. Profitability efficiency is further evidenced by a return on equity of 15.1% and a return on assets of 7.9%, metrics that reveal management effectiveness in generating returns on shareholder investments and utilizing total asset bases to produce earnings.
Valuation Assessment
The stock carries a trailing P/E ratio of 38.89 and a forward P/E of 19.56, and the disparity between these two multiples implies that the market expects earnings growth to significantly outpace current levels over the coming fiscal periods. The price-to-book ratio is recorded at 5.59, which indicates that the market is valuing the company at a significant premium over its net book value, reflecting high intangible assets, brand strength, or future growth expectations not captured in accounting book value. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 4.99 and an EV/EBITDA of 19.80, suggesting that investors are willing to pay a high multiple relative to sales and enterprise value adjusted for earnings quality. Price volatility metrics show a 52-week high of $404.87 and a 52-week low of $325.92, meaning the current price sits within a range defined by these extremes, though the specific current price point is not provided in the source data to calculate a precise percentage deviation. The beta value of 0.87 indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market fluctuations compared to the average equity.
Growth & Income
Revenue growth is reported at 11.4% year-over-year, while earnings growth reaches 55.9% year-over-year, indicating that earnings are growing substantially faster than revenue, which often implies successful cost management, mix shifts toward higher-margin products, or leverage effects as fixed costs are spread over growing sales. As a dividend payer, the company offers a dividend yield of 1.1% with a payout ratio of 40.5%, a figure that suggests the dividend is sustainable given that less than half of the net income is distributed to shareholders. The relatively high earnings growth rate relative to revenue growth supports the ability to maintain or potentially increase this payout over time without compromising reinvestment needs. Overall, the company presents a profile characterized by double-digit revenue expansion and accelerating earnings growth, complemented by a modest but stable dividend yield that provides income to shareholders alongside capital appreciation potential.